GCAR, Polaris initiate trial of glioblastoma therapy

The Global Coalition for Adaptive Research (GCAR) and Polaris Pharmaceuticals have initiated the Phase II/III Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial of ADI-PEG 20 to treat patients with newly diagnosed and recurrent glioblastoma (GBM), a deadly brain cancer.

Initially opened in July 2019, the patient-centered, adaptive platform trial for registration evaluated multiple therapies or combinations of therapies from different pharmaceutical partners simultaneously.